Heron Therapeutics (HRTX) Q2 2024 earnings summary

Executive summary

• Net product sales reached $36.0 million in Q2 2024, up from $31.8 million in Q2 2023, driven by increased sales across all product lines.

• Net loss for Q2 2024 was $9.2 million ($0.06 per share), a significant improvement from $42.1 million ($0.35 per share) in Q2 2023, reflecting lower operating expenses and cost discipline.

• Operating expenses reduced by over $36 million year-over-year, aided by restructuring and new management's focus on efficiency.

• ZYNRELEF VAN PDUFA goal date set for September 23, 2024, with launch expected before year-end and inclusion in the proposed 2025 NOPAIN Act.

• CrossLink partnership expanded to 561 trained representatives, targeting over 650 by VAN launch to drive ZYNRELEF adoption.

Financial highlights

• Q2 2024 net product sales: $36.0 million, up from $31.8 million in Q2 2023; YTD sales: $70.7 million, up from $61.4 million.

• Gross profit for Q2 2024 was $25.5 million (70.8%), up from $11.6 million (63.6%) in Q2 2023, driven by lower inventory write-offs.

• Net loss for Q2 2024 was $9.2 million, improved from $42.1 million in Q2 2023.

• Cash and short-term investments stood at $67.3 million as of June 30, 2024.

• Adjusted EBITDA for Q2 2024 was $1.7 million, reflecting operational improvements.

Outlook and guidance

• 2024 net product revenue guidance: $138.0–$158.0 million.

• Adjusted operating expenses guidance narrowed to $107.0–$111.0 million for 2024.

• Adjusted EBITDA guidance for 2024: $(10.0) million to $3.0 million.

• Gross margin expected to remain in the low-to-mid 70% range going forward.

• Management expects current cash and investments to fund operations for at least the next 12 months.